Effect of a DPP-4 inhibitor or an alpha-glucosidase inhibitor on endothelial function in patients with type 2 diabetes
Not Applicable
Completed
- Conditions
- Type 2 diabetic patients
- Registration Number
- JPRN-UMIN000003951
- Lead Sponsor
- Cardiovascular Dysfunction Study group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1, The patient under insulin treatment 2, The patient under alpha-GI or Gulinide treatment 3, Type 1 diabetes mellitus 4, Insufficiently controlled diabetes mellitus (HbA1c >= 9.0% ) 5, Insufficiently controlled hypertension (SBP>=160mmHg) 6, Severe ketosis, diabetic coma, or precoma within the past six months 7, Severe infectious disease, pre/ post operation or serious injury 8, Women who are pregnant, possibly pregnant, or are breastfeeding 9, Mild renal dysfunction (sCr>=1.5 mg/dl) 10, Hypersensitivity or allergy to sitagliptin and voglibose 11, Patients who are determined by the investigators to be unsuitable
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method % FMD after 12 weeks
- Secondary Outcome Measures
Name Time Method Change and % change in the following values in the 2 groups at 12 weeks after the initiation of treatment FPG HbA1c Incretin concentration (GIP, GLP-1) Endogenous insulin / glucagon C-peptide Lipid profile (TC, HDL-C, TG) Adiponectin CD34 hs-CRP PTX-3 MDA-LDL Urine-OHDG